

**Beneficiary Advisory Panel Handout
Uniform Formulary Decisions
March 2007**

PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Uniform Formulary Recommendations from the Feb 07 DoD P&T Committee Meeting

Drug Class	Generic Name (Brand)	Formulations	Generics Available?
Newer Sedative Hypnotics (SED-1s)			
Uniform Formulary	Zolpidem IR (Ambien)	tab	No
	Eszopiclone (Lunesta)	tab	No
Non-Formulary	Ramelteon (Rozerem)	tab	No
	Zaleplon (Sonata)	cap	No
	Zolpidem ER (Ambien CR)	tab	No
Recommended implementation period	90 days		
Narcotic Analgesics			
Uniform Formulary	High-potency single analgesic agents		
	Long-acting agents (≥ 12 hour duration)		
	Fentanyl transdermal system (Duragesic)	patch	Yes
	Morphine sulfate ER 24 hr (Kadian, Avinza)	cap	No
	Morphine sulfate ER 12 hr (MS Contin, Oramorph)	tab, soln, supp, inj	Yes
	Oxycodone ER (Oxycontin)	tabs	No
	Oxymorphone (Opana ER)	tabs	No
	Short acting agents (<12 hour duration)		
	Codeine	tabs, soln, inj	Yes
	Fentanyl citrate buccal (Fentora)	tabs	No
	Fentanyl citrate transmucosal (Actiq)	lozenges	Yes
	Hydromorphone (Dilaudid)	tab, inj, liquid	Yes, except for 1 mg tab
	Levorphanol (Levo-Dromoran)	tab, inj	Yes
	Meperidine (Demerol)	tab, soln, inj	Yes
	Meperidine / promethazine (Mepergan Fortis)	caps	Yes
	Methadone (Dolophine)	tab, oral conc, soln, inj	Yes
	Morphine sulfate IR	tabs	Yes
	Opium	tincture	Yes
	Opium / belladonna alkaloids	supp	Yes
	Oxycodone IR	caps, oral conc, soln	Yes
	Oxymorphone IR (Opana)	tabs	No
	High-potency combination agents		
	Oxycodone /APAP (e.g., Percocet, Tylox, others)	tab, cap, soln	Yes
	Oxycodone / ASA (Percodan)	tabs	Yes
	Low potency single analgesic agents		
	Buprenorphine (Subutex)	inj (excludes SL tabs)	Yes
	Butorphanol (Stadol)	nasal spray, inj	Yes
	Pentazocine / naloxone (Talwin NX)	tabs	Yes
	Propoxyphene (Darvon)	caps, tabs	Yes
	Nalbuphine (Nubain) not a controlled substance)	Inj	Yes
	Tramadol IR(Ultram) not a controlled substance	tab	Yes
	Low potency combination agents		
Codeine / APAP (Tylenol with codeine)	tabs, elixir, oral susp	Yes	

Drug Class	Generic Name (Brand)	Formulations	Generics Available?
	Codeine / ASA	tabs	Yes
	Codeine / ASA / carisoprodol (Soma)	tabs	Yes
	Codeine / caffeine / butalbital / APAP (Fioricet with codeine)	caps	Yes
	Codeine / caffeine / butalbital / ASA (Fiorinal with caffeine)	caps, tabs	Yes
	Dihydrocodeine / caffeine / APAP e.g., Panlor DC, Panlor SS)	caps, tabs	Yes
	Dihydrocodeine / caffeine / ASA (Synalgos-DC)	caps	Yes
	Hydrocodone / APAP (e.d.g, Lortab, Lorcet, Vicoden, others)	caps	Yes
	Pentazocine / APAP (Talacen)	tabs	Yes
	Propoxyphene / APAP (Darvocet)	tabs	Yes
	Propoxyphene / ASA / caffeine (Darvon Compound 65)	caps	Yes
	Tramadol/APAP (Ultracet) not a controlled substance	tab	Yes
Non-Formulary	Low potency single analgesic agents		
	Tramadol extended release (Ultram ER)	tab	No
Recommended implementation period	90 days		
Glaucoma Agents			
Uniform Formulary	Prostaglandin Analogs		
	Bimatoprost (Lumigan)	ophthalmic soln	No
	Latanoprost (Xalatan)	ophthalmic soln	No
	Beta Blockers		
	Betaxolol (Betoptic, Betoptic-S)	ophthalmic soln	Yes to Betoptic, No to Betoptic-S
	Carteolol (Ocupress)	ophthalmic soln	Yes
	Levobunolol (Betagan)	ophthalmic soln	Yes
	Metipranolol (Optipranolol)	ophthalmic soln	Yes
	Timolol maleate (Timoptic)	ophthalmic soln	Yes
	Timolol maleate gel forming solution (Timoptic XE)	ophthalmic gel	Yes
	Carbonic Anhydrase Inhibitor /Combinations		
	Dorzolamide (Trusopt)	ophthalmic soln	No
	Dorzolamide / timolol (Cosopt)	ophthalmic soln	No
	Alpha 2 Adrenergics		
	Brimonidine BAK 0.2% (brand name D/C'd)	ophthalmic soln	Yes
	Brimonidine purite 0.15%, 0.1% (Alphagan P)	ophthalmic soln	No
	Apraclonidine (Iopidine)	ophthalmic soln	No
	Adrenergics, Cholinergics, Cholinesterase Inhibitors		
	Dipivefrin (Propine)	ophthalmic soln	Yes
	Acetylcholine (Miochol-E)	ophthalmic soln	No
	Carbachol (Isopto Carbachol)	ophthalmic soln	No
Pilocarpine (Pilocar, Pilopine HS)	ophthalmic soln and gel	Yes to soln, No to gel	
Echothiophate (Phospholine iodide)	ophthalmic soln	No	
Non-Formulary	Prostaglandin Analogs		
	Travoprost (Travatan, Travatan Z)	ophthalmic soln	No

Drug Class	Generic Name (Brand)	Formulations	Generics Available?
	Beta blockers		
	Timolol maleate (Istalol)	ophthalmic soln	No
	Timolol hemihydrate (Betimol)	ophthalmic soln	No
	Carbonic Anhydrase Inhibitor		
	Brinzolamide (Azopt)	ophthalmic soln	No
Recommended implementation period	90 days		
Monoamine Oxidase (MOA) Inhibitor Antidepressants			
Uniform Formulary	Isocarboxazid (Marplan)	tab	No
	Phenelzine (Nardil)	tab	No
	Tranylcypromine (Parnate)	tab	Yes
Non-Formulary	Selegiline transdermal system (Emsam)	patch	No
Recommended implementation period	90 days		


APAP: acetaminophen (Tylenol); ASA: aspirin; BAK: benzalkonium chloride preservative; cap: capsule; conc: concentrate; ER: extended release; inj: injection; IR: immediate release; SL: sublingual; soln: solution; SR: sustained release; supp: suppository; tab: tablet

Table 2: Uniform Formulary Recommendations from the Feb 07 DoD P&T Committee Meeting for New Drugs in Classes Previously Reviewed for UF Status

New Drugs in Classes Previously Reviewed for UF Status		
Proton Pump Inhibitors (PPIs)		
Recommendation at Feb 2007 meeting		
Older Antiemetics	UF	Over the Counter Omeprazole magnesium (Prilosec OTC)
	Non-formulary	N/A
Recommended implementation period	90 days	
Existing UF Status of PPIs (Feb 2005) & Feb 2007 recommendations		
PPIs	UF	Over the Counter Omeprazole magnesium (Prilosec OTC)
		Omeprazole (Prilosec, generic)
		Lansoprazole (Prevacid)
		Pantoprazole (Protonix)
		Rabeprazole (Aciphex)
	Non-formulary	Esomeprazole (Nexium)

Figure 1:

MHS Rxs for Newer Sedative Hypnotics Oct 04 – Dec 06



Source: PDTS

1

Figure 2. Prior Authorization Process for SED-1 Agents Other than Zolpidem IR (Ambien)

**Figure 1. TRICARE Pharmacy Network Step Therapy Process
Newer Sedative Hypnotics (SED-1)**




Figure 3: Narcotic Analgesics




Figure 4:





Figure 5:

Prostaglandins: MHS Rx's, Oct 04 - Dec 06



Source: PDTS

Figure 6:

Beta Blockers: MHS Rx's, Oct 04 - Dec 06




Figure 7:




Figure 8:




Table 3: Uniform Formulary Implementation Plan Summary

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 07	Newer Sedative Hypnotics	<ul style="list-style-type: none"> Ramelteon (Rozerem) Zaleplon (Sonata) Zolpidem ER (Ambien CR) 	40,447	5,878	31,550	3,019	90 days	First time automated PA with step edit
Feb 07	Narcotic Analgesics	<ul style="list-style-type: none"> Tramadol ER (Ultram ER) 	1,088	0	46	1,042	90 days	Small number of beneficiaries affected
Feb 07	Glaucoma Agents	<ul style="list-style-type: none"> Travoprost (Travatan, Travatan Z) Timolol maleate (Istalol) Timolol hemihydrate (Betimol) Brinzolamide (Azopt) 	17,139	1,735	12,267	3,117	90 days	Small number of beneficiaries affected
Feb 07	MAOI Antidepressants	<ul style="list-style-type: none"> Selegiline transdermal system (Emsam) 	168	0	157	11	90 days	Small number of beneficiaries affected
Nov 06	ADHD	<ul style="list-style-type: none"> Dexmethylphenidate IR (Focalin) Dexmethylphenidate SODAS (Focalin XR) Methylphenidate transdermal patch (Daytrana) 	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected
Nov 06	Older Sedative Hypnotics	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	TZDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	H2 Antagonists / GI protectants	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	Antilipidemic Agents	<ul style="list-style-type: none"> Rosuvastatin (Crestor) Atorvastatin / amiodipine (Caduet) 	44,078	851	36,133	6,921	1 Feb 07 (90 days)	Small number of beneficiaries affected

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
May 06	Antiemetics	<ul style="list-style-type: none"> Dolasetron (Anzemet) 	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)
May 06 update for new drugs Nov 06	Contraceptive Agents	<ul style="list-style-type: none"> EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale) EE 25 mcg / norethindrone 0.4 mg (Ovcon 35) EE 50 mcg / norethindrone 1 mg (Ovcon 50) EE 20/30/35 mcg / norethindrone 1 mg (Eastrostep Fe) 	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply
		<ul style="list-style-type: none"> EE 20 mcg/1 mg norethindrone-24 day regimen (Loestrin 24 Fe) EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique) 	Seasonique 161 (from Apr 06-Oct 06) Loestrin 24 Fe: 2,227 (from Apr 06-Oct 06)	0 Rx	112 Rx	4 Rx	Jan 24 07 (60 days; to coincide with Seasonal)	Small number of beneficiaries affected
Feb 06	OABs	<ul style="list-style-type: none"> tolterodine IR (Detrol) oxybutynin patch (Oxytrol) trospium (Sanctura) 	19,118	2,596	13,471	3,051	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 06	Misc Anti-hypertensive Agents	<ul style="list-style-type: none"> felodipine/enalapril (Lexxel) verapamil/trandolapril (Tarka) 	5,946	336	4,472	1,138	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted
Feb 06	GABA-analogs	<ul style="list-style-type: none"> pregabalin (Lyrica) 	30,649	1,120	27,566	1,963	28 Jun 06 (60 days)	Small number of beneficiaries affected
Nov 05	Alzheimer's Drugs	<ul style="list-style-type: none"> tacrine (Cognex) 	5	0	3	2	19 Apr 06 (90 days)	Small number of beneficiaries affected
Nov 05	Nasal Corticosteroid Agents	<ul style="list-style-type: none"> beclomethasone dipropionate (Beconase AQ, Vancenase AQ) budesonide (Rhinocort Aqua) triamcinolone (Nasacort AQ) 	96,999	13,556	73,381	10,062	19 Apr 06 (90 days)	Substantial number of beneficiaries affected
Nov 05	Macrolide/Ketolide Antibiotics	<ul style="list-style-type: none"> azithromycin 2 gm (Zmax) telithromycin (Ketek) 	Total number not provided; antibiotics are used to treat acute infections				22 Mar 06 (60 days)	Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change
Nov 05	Antidepressants	<ul style="list-style-type: none"> paroxetine HCl CR (Paxil) fluoxetine 90 mg for weekly administration (Prozac Weekly) fluoxetine in special packaging for PMDD (Sarafem) escitalopram (Lexapro) duloxetine (Cymbalta) bupropion extended release (Wellbutrin XL) 	182,916	52,624	118,582	11,710	19 Jul 06 (180 days)	Substantial number of beneficiaries affected
Aug 05	Alpha Blockers for BPH	<ul style="list-style-type: none"> tamsulosin (Flomax) 	89,926	26,692	47,674	15,560	15 Feb 06 (120 days)	Substantial number of beneficiaries affected

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
		<ul style="list-style-type: none"> ▪ amlodipine (Norvasc) ▪ isradipine IR (Dynacirc) ▪ isradipine ER (Dynacirc CR) ▪ nicardipine IR (Cardene, generics) ▪ nicardipine SR (Cardene SR) ▪ verapamil ER (Verelan) ▪ verapamil ER for bedtime dosing (Verelan PM, Covera HS) ▪ diltiazem ER for bedtime dosing (Cardizem LA) 	274,616	133,794	101,345	39,477	15 Mar 06 (150 days)	Substantial number of beneficiaries affected
Aug 05	CCBs	<ul style="list-style-type: none"> ▪ moexipril (Univas), ▪ moexipril / HCTZ (Uniretic) ▪ perindopril (Aceon) ▪ quinapril (Accupril) ▪ quinapril / HCTZ (Accuretic) ▪ ramipril (Altace) 	158,101	77,159	57,982	22,959	16 Feb 06 (120 days)	Substantial number of beneficiaries affected
May 05	PDE-5 Inhibitors	<ul style="list-style-type: none"> ▪ sildenafil (Viagra) ▪ tadalafil (Cialis) 	128,007	55,161	49,850	22,996	12 Oct 05 (90 days)	Substantial number of beneficiaries affected
May 05 updated for new drug Nov 06	Topical Antifungals*	<ul style="list-style-type: none"> ▪ econazole ▪ ciclopirox ▪ oxiconazole (Oxistat) ▪ sertaconazole (Ertaczo) ▪ sulconazole (Exelderm) ▪ miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion) 	49,743	14,266	33,430	2,047	17 Aug 05 (30 days)	Medication used to treat acute (not chronic) infections not likely to require therapy change
May 05	MS-DMDs	-	581 (Apr 06-Oct 06) (UU not applicable)	7	571	3	21 Feb 07 (60 days)	Small numbers of beneficiaries affected
			0	0	0	0	Not applicable	No medications moved to non-formulary status

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 05	ARBs	<ul style="list-style-type: none"> • losartan (Teveten) • losartan/HCTZ (Teveten HCT) 	2,184	13	1,644	527	17 Jul 05 (90 days)	Recommended 30-day implementation-overturned; 90-day BAP recommendation accepted
Feb 05	PPIs	<ul style="list-style-type: none"> • esomeprazole (Nexium) 	138,739	6,691	117,520	14,528	17 Jul 05 (90 days)	Substantial number of beneficiaries affected

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary

CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release

ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; OABs = Overactive Bladder Medications;

PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])